BioDuro opened a new laboratory in Shanghai, China on Wednesday to offer a range of customized biopharma services for its Asia Pacific clients.
“The 72,000-square-foot lab—which includes 20,000 square feet of office space—offers integrated drug metabolism and pharmacokinetic (DMPK), bioanalytical, chemistry, discovery biology and oncology pharmacology services,” Jasmine Cui, Ph.D., General Manager and Chief Scientific Officer of BioDuro, told Outsourcing-Pharma.com.
“This new lab will allow us to meet the business needs of our clients more effectively by streamlining the discovery and development process, and by providing greater continuity and consistency throughout the stages of development.”
BioDuro, a drug discovery firm acquired by PPD (Pharmaceutical Product Development) in 2009 , previously worked with AstraZeneca and Roche on discovery projects. The subsidiary's clients will be able to take advantage of a host of other clinical research serves, as well as a library of assays for testing.
Michael Clay, vice president of clinical development for PPD Asia Pacific, told Outsourcing-pharma.com that for the past 15 years PPD has been working in Asia Pacific and “developing our capabilities in those countries during that time and expanding our capabilities throughout the region… At PPD we can support our clients all the way from drug discovery to the clinical trial process to registration of those products in Asia Pacific or anywhere globally.”
The new laboratory also adds to the company’s existing presence in Beijing, China. BioDuro also has an 110,000-square-foot laboratory in Beijing.
Since February, PPD has expanded in all directions globally. The CRO’s central lab services in Brussels and Singapore expanded for clients with microbiology testing needs.
In addition, PPD in April bolstered its bioassay and bioanalytical services in Brazil and Wisconsin . The company now has offices in 46 countries.